Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma J Williams

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 29, 2019
Managing the Risk of Aggressive Dog Behavior: Investigating the Influence of Owner Threat and Efficacy PerceptionsEmma J Williams, Emily Blackwell
Plos One|April 11, 2013
Telling lies: the irrepressible truth?Emma J Williams, Lewis A Bott, John Patrick, et al.
Molecular and Cellular Neurosciences|October 23, 2012
The molecular basis of the cooperation between EGF, FGF and eCB receptors in the regulation of neural stem cell functionPhilipp Sütterlin, Emma J Williams, David Chambers, et al.
Neurocase|December 25, 2002
Detecting residual cognitive function in persistent vegetative stateAdrian M Owen, David K Menon, Ingrid S Johnsrude, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2008
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidinesCatherine Bardelle, Darren Cross, Sara Davenport, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2008
Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidinesCatherine Bardelle, Tanya Coleman, Darren Cross, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokineticsPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2007
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Bernard C Barlaam, Robert H Bradbury, et al.
Journal of Medicinal Chemistry|February 3, 2015
Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2Kurt G Pike, Jeff Morris, Linette Ruston, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 29, 2019
Managing the Risk of Aggressive Dog Behavior: Investigating the Influence of Owner Threat and Efficacy PerceptionsEmma J Williams, Emily Blackwell
Plos One|April 11, 2013
Telling lies: the irrepressible truth?Emma J Williams, Lewis A Bott, John Patrick, et al.
Molecular and Cellular Neurosciences|October 23, 2012
The molecular basis of the cooperation between EGF, FGF and eCB receptors in the regulation of neural stem cell functionPhilipp Sütterlin, Emma J Williams, David Chambers, et al.
Neurocase|December 25, 2002
Detecting residual cognitive function in persistent vegetative stateAdrian M Owen, David K Menon, Ingrid S Johnsrude, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2008
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidinesCatherine Bardelle, Darren Cross, Sara Davenport, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2008
Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidinesCatherine Bardelle, Tanya Coleman, Darren Cross, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokineticsPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2005
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketPeter Ballard, Robert H Bradbury, Craig S Harris, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2007
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Bernard C Barlaam, Robert H Bradbury, et al.
Journal of Medicinal Chemistry|February 3, 2015
Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2Kurt G Pike, Jeff Morris, Linette Ruston, et al.
Pageof 1